Login Register Cart 0
Review Article

ST2对急性冠状动脉综合征和心力衰竭的预测作用

卷 27, 期 27, 2020

页: [4479 - 4493] 页: 15

弟呕挨: 10.2174/0929867326666191016121630

价格: $65

摘要

大量的研究已经阐明了利用新的生物标记物来促进不同疾病患者的诊断和预后。可溶性ST2 (sST2:可溶性抑制肿瘤发生2)是心力衰竭谱中最重要的生物标志物之一，参与炎症、纤维化和心脏应激。在2017年修订的ACC/AHA/HFSA中，对心力衰竭ST2管理的重点更新指南给出了对心力衰竭患者最佳风险评估的iia级推荐。许多研究表明，ST2的基线测量和连续测量都可以准确预测急性冠状动脉综合征和心力衰竭患者未来的心血管事件。因此，在本综述中，我们将讨论ST2在急性冠脉综合征、急性和慢性心力衰竭患者的预后意义。

关键词: 急性冠状动脉综合征(ACS)，生物指标，冠心病，心衰，预后。

« Previous Next »
[1]
The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur. Heart J., 2012, 33(14), 1750-1757.
[http://dx.doi.org/10.1093/eurheartj/ehr254] [PMID: 21821849]
[2]
Oikonomou, E.; Zografos, T.; Papamikroulis, G.A.; Siasos, G.; Vogiatzi, G.; Theofilis, P.; Briasoulis, A.; Papaioannou, S.; Vavuranakis, M.; Gennimata, V.; Tousoulis, D. Biomarkers in atrial fibrillation and heart failure. Curr. Med. Chem., 2019, 26(5), 873-887.
[http://dx.doi.org/10.2174/0929867324666170830100424] [PMID: 28875838]
[3]
Tousoulis, D.; Drolias, A.; Antoniades, C.; Vasiliadou, C.; Marinou, K.; Latsios, G.; Stefanadi, E.; Gounari, P.; Siasos, G.; Papageorgiou, N.; Trikas, A.; Stefanadis, C. Antidepressive treatment as a modulator of inflammatory process in patients with heart failure: effects on proinflammatory cytokines and acute phase protein levels. Int. J. Cardiol., 2009, 134(2), 238-243.
[http://dx.doi.org/10.1016/j.ijcard.2008.02.013] [PMID: 18579238]
[4]
Bocchi, E.A. Heart failure in South America. Curr. Cardiol. Rev., 2013, 9(2), 147-156.
[http://dx.doi.org/10.2174/1573403X11309020007] [PMID: 23597301]
[5]
Tousoulis, D.; Charakida, M.; Stefanadi, E.; Siasos, G.; Latsios, G.; Stefanadis, C. Statins in heart failure. Beyond the lipid lowering effect. Int. J. Cardiol., 2007, 115(2), 144-150.
[http://dx.doi.org/10.1016/j.ijcard.2006.03.094] [PMID: 17175040]
[6]
Wang, J.; Tan, G.J.; Han, L.N.; Bai, Y.Y.; He, M.; Liu, H.B. Novel biomarkers for cardiovascular risk prediction. J. Geriatr. Cardiol., 2017, 14(2), 135-150.
[http://dx.doi.org/10.11909/j.issn.1671-5411.2017.02.008] [PMID: 28491088]
[7]
Tominaga, S. A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett., 1989, 258(2), 301-304.
[http://dx.doi.org/10.1016/0014-5793(89)81679-5] [PMID: 2532153]
[8]
Weinberg, E.O.; Shimpo, M.; De Keulenaer, G.W.; MacGillivray, C.; Tominaga, S.; Solomon, S.D.; Rouleau, J.L.; Lee, R.T. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation, 2002, 106(23), 2961-2966.
[http://dx.doi.org/10.1161/01.CIR.0000038705.69871.D9] [PMID: 12460879]
[9]
Tominaga, S.; Yokota, T.; Yanagisawa, K.; Tsukamoto, T.; Takagi, T.; Tetsuka, T. Nucleotide sequence of a complementary DNA for human ST2. Biochim. Biophys. Acta, 1992, 1171(2), 215-218.
[http://dx.doi.org/10.1016/0167-4781(92)90125-J] [PMID: 1482686]
[10]
Dale, M.; Nicklin, M.J. Interleukin-1 receptor cluster: gene organization of IL1R2, IL1R1, IL1RL2 (IL-1Rrp2), IL1RL1 (T1/ST2), and IL18R1 (IL-1Rrp) on human chromosome 2q. Genomics, 1999, 57(1), 177-179.
[http://dx.doi.org/10.1006/geno.1999.5767] [PMID: 10191101]
[11]
Gao, Q.; Li, Y.; Li, M. The potential role of IL-33/ST2 signaling in fibrotic diseases. J. Leukoc. Biol., 2015, 98(1), 15-22.
[http://dx.doi.org/10.1189/jlb.3RU0115-012R] [PMID: 25881899]
[12]
Tago, K.; Noda, T.; Hayakawa, M.; Iwahana, H.; Yanagisawa, K.; Yashiro, T.; Tominaga, S. Tissue distribution and subcellular localization of a variant form of the human ST2 gene product, ST2V. Biochem. Biophys. Res. Commun., 2001, 285(5), 1377-1383.
[http://dx.doi.org/10.1006/bbrc.2001.5306] [PMID: 11478810]
[13]
Bergers, G.; Reikerstorfer, A.; Braselmann, S.; Graninger, P.; Busslinger, M. Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor. EMBO J., 1994, 13(5), 1176-1188.
[http://dx.doi.org/10.1002/j.1460-2075.1994.tb06367.x] [PMID: 8131748]
[14]
Iwahana, H.; Yanagisawa, K.; Ito-Kosaka, A.; Kuroiwa, K.; Tago, K.; Komatsu, N.; Katashima, R.; Itakura, M.; Tominaga, S. Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. Eur. J. Biochem., 1999, 264(2), 397-406.
[http://dx.doi.org/10.1046/j.1432-1327.1999.00615.x] [PMID: 10491084]
[15]
Thomassen, E.; Kothny, G.; Haas, S.; Danescu, J.; HA1/4ltner, L.; DArmer, P.; Werenskiold, A.K. Role of cell type-specific promoters in the developmental regulation of T1, an interleukin 1 receptor homologue. Cell Growth Differ., 1995, 6(2), 179-184.
[PMID: 7756176]
[16]
Bayes-Genis, A.; Januzzi, J.L. The international ST2 consensus panel: introduction. Am. J. Cardiol., 2015, 115(7)(Suppl.), 1B-2B.
[http://dx.doi.org/10.1016/j.amjcard.2015.01.033] [PMID: 25665760]
[17]
Schmitz, J.; Owyang, A.; Oldham, E.; Song, Y.; Murphy, E.; McClanahan, T.K.; Zurawski, G.; Moshrefi, M.; Qin, J.; Li, X.; Gorman, D.M.; Bazan, J.F.; Kastelein, R.A. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity, 2005, 23(5), 479-490.
[http://dx.doi.org/10.1016/j.immuni.2005.09.015] [PMID: 16286016]
[18]
Hodzic, Z.; Schill, E.M.; Bolock, A.M.; Good, M. IL-33 and the intestine: The good, the bad, and the inflammatory. Cytokine, 2017, 100, 1-10.
[http://dx.doi.org/10.1016/j.cyto.2017.06.017] [PMID: 28687373]
[19]
Januzzi, J.L.; Pascual-Figal, D.; Daniels, L.B. ST2 testing for chronic heart failure therapy monitoring: the International ST2 Consensus Panel. Am. J. Cardiol., 2015, 115(7)(Suppl.), 70B-75B.
[http://dx.doi.org/10.1016/j.amjcard.2015.01.044] [PMID: 25670638]
[20]
Siasos, G.; Lazaros, G.; Oikonomou, E.; Zografos, T.; Athanasiou, D.; Vavuranakis, M.; Antonopoulos, A.; Tsigkou, V.; Stefanadis, C.; Papavassiliou, A.G.; Tousoulis, D. Different prognostic significance of cardiac troponin at presentation and peak cardiac troponin in patients with non-ST segment elevation myocardial infarction. Cardiology, 2016, 134(4), 384-388.
[http://dx.doi.org/10.1159/000445104] [PMID: 27116688]
[21]
Brown, A.M.; Wu, A.H.B.; Clopton, P.; Robey, J.L.; Hollander, J.E. ST2 in emergency department chest pain patients with potential acute coronary syndromes. Ann. Emerg. Med., 2007, 50(2), 153-158.
[http://dx.doi.org/10.1016/j.annemergmed.2007.02.015] [PMID: 17466411]
[22]
Weir, R.A.; Miller, A.M.; Murphy, G.E.; Clements, S.; Steedman, T.; Connell, J.M.; McInnes, I.B.; Dargie, H.J.; McMurray, J.J. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J. Am. Coll. Cardiol., 2010, 55(3), 243-250.
[http://dx.doi.org/10.1016/j.jacc.2009.08.047] [PMID: 20117403]
[23]
Aldous, S.J.; Richards, A.M.; Troughton, R.; Than, M. ST2 has diagnostic and prognostic utility for all-cause mortality and heart failure in patients presenting to the emergency department with chest pain. J. Card. Fail., 2012, 18(4), 304-310.
[http://dx.doi.org/10.1016/j.cardfail.2012.01.008] [PMID: 22464771]
[24]
Barbarash, O.; Gruzdeva, O.; Uchasova, E.; Dyleva, Y.; Belik, E.; Akbasheva, O.; Karetnikova, V.; Shilov, A. Prognostic value of soluble ST2 during hospitalization for ST-segment elevation myocardial infarction. Ann. Lab. Med., 2016, 36(4), 313-319.
[http://dx.doi.org/10.3343/alm.2016.36.4.313] [PMID: 27139603]
[25]
Jha, D.; Goenka, L.; Ramamoorthy, T.; Sharma, M.; Dhandapani, V.E.; George, M. Prognostic role of soluble ST2 in acute coronary syndrome with diabetes. Eur. J. Clin. Invest., 2018, 48(9) e12994.s
[http://dx.doi.org/10.1111/eci.12994] [PMID: 29992539]
[26]
Shimpo, M.; Morrow, D.A.; Weinberg, E.O.; Sabatine, M.S.; Murphy, S.A.; Antman, E.M.; Lee, R.T. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation, 2004, 109(18), 2186-2190.
[http://dx.doi.org/10.1161/01.CIR.0000127958.21003.5A] [PMID: 15117853]
[27]
Sabatine, M.S.; Morrow, D.A.; Higgins, L.J.; MacGillivray, C.; Guo, W.; Bode, C.; Rifai, N.; Cannon, C.P.; Gerszten, R.E.; Lee, R.T. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation, 2008, 117(15), 1936-1944.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.107.728022] [PMID: 18378613]
[28]
Gruzdeva, O.; Dyleva, Y.; Uchasova, E.; Akbasheva, O.; Karetnikova, V.; Kashtalap, V.; Shilov, A.; Polikutina, O.; Slepynina, Y.; Barbarash, O. Biological markers and cardiac remodelling following the myocardial infarction. Aging (Albany NY), 2019, 11(11), 3523-3535.
[http://dx.doi.org/10.18632/aging.101994] [PMID: 31182683]
[29]
Marino, R.; Magrini, L.; Orsini, F.; Russo, V.; Cardelli, P.; Salerno, G.; Hur, M.; Di Somma, S. GREAT NETWORK. Comparison between soluble ST2 and high-sensitivity troponin i in predicting short-term mortality for patients presenting to the emergency department with chest pain. Ann. Lab. Med., 2017, 37(2), 137-146.
[http://dx.doi.org/10.3343/alm.2017.37.2.137] [PMID: 28029000]
[30]
Dhillon, O.S.; Narayan, H.K.; Khan, S.Q.; Kelly, D.; Quinn, P.A.; Squire, I.B.; Davies, J.E.; Ng, L.L. Pre-discharge risk stratification in unselected STEMI: is there a role for ST2 or its natural ligand IL-33 when compared with contemporary risk markers? Int. J. Cardiol., 2013, 167(5), 2182-2188.
[http://dx.doi.org/10.1016/j.ijcard.2012.05.073] [PMID: 22835988]
[31]
Demyanets, S.; Kaun, C.; Pentz, R.; Krychtiuk, K.A.; Rauscher, S.; Pfaffenberger, S.; Zuckermann, A.; Aliabadi, A.; GrAger, M.; Maurer, G.; Huber, K.; Wojta, J. Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature. J. Mol. Cell. Cardiol., 2013, 60, 16-26.
[http://dx.doi.org/10.1016/j.yjmcc.2013.03.020] [PMID: 23567618]
[32]
O’Donoghue, M.L.; Morrow, D.A.; Cannon, C.P.; Jarolim, P.; Desai, N.R.; Sherwood, M.W.; Murphy, S.A.; Gerszten, R.E.; Sabatine, M.S. Multimarker Risk Stratification in Patients With Acute Myocardial Infarction. J. Am. Heart Assoc., 2016, 5(5) e002586
[http://dx.doi.org/10.1161/JAHA.115.002586] [PMID: 27207959]
[33]
Liu, X.; Hu, Y.; Huang, W.; Zhang, G.; Cao, S.; Yan, X.; Li, L.; Zhang, L.; Zheng, X. Soluble ST2 for prediction of clinical outcomes in patients with ST-segment elevation myocardial infarction receiving primary PCI. Int. Heart J., 2019, 60(1), 19-26.
[http://dx.doi.org/10.1536/ihj.18-020] [PMID: 30464124]
[34]
Kercheva, M.; Ryabova, T.; Gusakova, A.; Suslova, T.E.; Ryabov, V.; Karpov, R.S. Serum soluble ST2 and adverse left ventricular remodeling in patients with ST-segment elevation myocardial infarction. Clin. Med. Insights Cardiol., 2019, 13, 1179546819842804
[http://dx.doi.org/10.1177/1179546819842804] [PMID: 31065219]
[35]
Minana, G.; Nunez, J.; Bayes-Genis, A.; Revuelta-Lopez, E.; Rios-Navarro, C.; Nunez, E.; Chorro, F.J.; Lopez-Lereu, M.P.; Monmeneu, J.V.; Lupon, J.; Bodi, V. ST2 and left ventricular remodeling after ST-segment elevation myocardial infarction: A cardiac magnetic resonance study. Int. J. Cardiol., 2018, 270, 336-342.
[http://dx.doi.org/10.1016/j.ijcard.2018.06.073] [PMID: 29954670]
[36]
Huang, W.P.; Zheng, X.; He, L.; Su, X.; Liu, C.W.; Wu, M.X. Role of soluble ST2 levels and beta-blockers dosage on cardiovascular events of patients with unselected ST-segment elevation myocardial infarction. Chin. Med. J. (Engl.), 2018, 131(11), 1282-1288.
[http://dx.doi.org/10.4103/0366-6999.232819] [PMID: 29786039]
[37]
Eggers, K.M.; Armstrong, P.W.; Califf, R.M.; Simoons, M.L.; Venge, P.; Wallentin, L.; James, S.K. ST2 and mortality in non-ST-segment elevation acute coronary syndrome. Am. Heart J., 2010, 159(5), 788-794.
[http://dx.doi.org/10.1016/j.ahj.2010.02.022] [PMID: 20435187]
[38]
Dhillon, O.S.; Narayan, H.K.; Quinn, P.A.; Squire, I.B.; Davies, J.E.; Ng, L.L. Interleukin 33 and ST2 in non-ST-elevation myocardial infarction: comparison with Global Registry of Acute Coronary Events Risk Scoring and NT-proBNP. Am. Heart J., 2011, 161(6), 1163-1170.
[http://dx.doi.org/10.1016/j.ahj.2011.03.025] [PMID: 21641364]
[39]
Kohli, P.; Bonaca, M.P.; Kakkar, R.; Kudinova, A.Y.; Scirica, B.M.; Sabatine, M.S.; Murphy, S.A.; Braunwald, E.; Lee, R.T.; Morrow, D.A. Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. Clin. Chem., 2012, 58(1), 257-266.
[http://dx.doi.org/10.1373/clinchem.2011.173369] [PMID: 22096031]
[40]
Jenkins, W.S. Prognostic value of soluble ST2 after myocardial infarction: a community perspective. Am. J. Med., 2017, 130(9), 1112 e9-1112 e15.
[http://dx.doi.org/10.1016/j.amjmed.2017.02.034]
[41]
Kokkoz, Ç.; Bilge, A.; Irik, M.; Dayangaç, H.I.; Hayran, M.; Akarca, F.K.; Erdem, N.B.; Çavuş, M. Prognostic value of plasma ST2 in patients with non-ST segment elevation acute coronary syndrome. Turk. J. Emerg. Med., 2018, 18(2), 62-66.
[http://dx.doi.org/10.1016/j.tjem.2018.01.003] [PMID: 29922732]
[42]
Dieplinger, B.; Egger, M.; Haltmayer, M.; Kleber, M.E.; Scharnagl, H.; Silbernagel, G.; de Boer, R.A.; Maerz, W.; Mueller, T. Increased soluble ST2 predicts long-term mortality in patients with stable coronary artery disease: results from the Ludwigshafen risk and cardiovascular health study. Clin. Chem., 2014, 60(3), 530-540.
[http://dx.doi.org/10.1373/clinchem.2013.209858] [PMID: 24401186]
[43]
Lepojärvi, E.S.; Piira, O.P.; PAAkkA, E.; Lammentausta, E.; Risteli, J.; Miettinen, J.A.; PerkiAmAki,, J.S.; Huikuri, H.V.; Junttila, M.J. Serum PINP, PIIINP, galectin-3, and ST2 as surrogates of myocardial fibrosis and echocardiographic left venticular diastolic filling properties. Front. Physiol., 2015, 6, 200.
[http://dx.doi.org/10.3389/fphys.2015.00200] [PMID: 26217237]
[44]
Siasos, G.; Tousoulis, D.; Michalea, S.; Oikonomou, E.; Vavuranakis, M.; Athanasiou, D.; Tourikis, P.; Gouliopoulos, N.; Miliou, A.; Mourouzis, K.; Limperi, M.; Mazaris, S.; Papavassiliou, A.G.; Stefanadis, C. Novel biomarkers assessing renal function in heart failure: relation to inflammatory status and cardiac remodelling. Curr. Med. Chem., 2014, 21(34), 3976-3983.
[http://dx.doi.org/10.2174/0929867321666140826114656] [PMID: 25174929]
[45]
Tousoulis, D.; Michalea, S.; Siasos, G.; Oikonomou, E.; Athanasiou, D.; Tourikis, P.; Kokkou, E.; Mazaris, S.; Konsola, T.; Papageorgiou, N.; Stefanadis, C. Cystatin-C serum levels and vascular function in heart failure. Int. J. Cardiol., 2014, 173(3), 542-544.
[http://dx.doi.org/10.1016/j.ijcard.2014.03.083] [PMID: 24704396]
[46]
Tousoulis, D.; Kampoli, A.M.; Papageorgiou, N.; Antoniades, C.; Siasos, G.; Latsios, G.; Tsiamis, E.; Stefanadis, C. Matrix metallopropteinases in heart failure. Curr. Top. Med. Chem., 2012, 12(10), 1181-1191.
[http://dx.doi.org/10.2174/1568026611208011181] [PMID: 22519448]
[47]
Oikonomou, E.; Tousoulis, D.; Siasos, G.; Zaromitidou, M.; Papavassiliou, A.G.; Stefanadis, C. The role of inflammation in heart failure: new therapeutic approaches. Hellenic J. Cardiol., 2011, 52(1), 30-40.
[PMID: 21292605]
[48]
Ponikowski, P.; Voors, A.A.; Anker, S.D.; Bueno, H.; Cleland, J.G.; Coats, A.J.; Falk, V.; Gonzalez-Juanatey, J.R.; Harjola, V.P.; Jankowska, E.A.; Jessup, M.; Linde, C.; Nihoyannopoulos, P.; Parissis, J.T.; Pieske, B.; Riley, J.P.; Rosano, G.M.; Ruilope, L.M.; Ruschitzka, F.; Rutten, F.H.; van der Meer, P. Authors/Task Force Members Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail., 2016, 18(8), 891-975.
[http://dx.doi.org/10.1002/ejhf.592] [PMID: 27207191]
[49]
Tousoulis, D.; Oikonomou, E.; Siasos, G.; Stefanadis, C. Statins in heart failure--With preserved and reduced ejection fraction. An update. Pharmacol. Ther., 2014, 141(1), 79-91.
[http://dx.doi.org/10.1016/j.pharmthera.2013.09.001] [PMID: 24022031]
[50]
Siasos, G.; Tousoulis, D.; Oikonomou, E.; Kokkou, E.; Mazaris, S.; Konsola, T.; Stefanadis, C. Novel biomarkers in heart failure: usefulness in clinical practice. Expert Rev. Cardiovasc. Ther., 2014, 12(3), 311-321.
[http://dx.doi.org/10.1586/14779072.2014.890516] [PMID: 24552543]
[51]
Tousoulis, D.; Oikonomou, E.; Siasos, G.; Chrysohoou, C.; Charakida, M.; Trikas, A.; Siasou, Z.; Limperi, M.; Papadimitriou, E.D.; Papavassiliou, A.G.; Stefanadis, C. Predictive value of biomarkers in patients with heart failure. Curr. Med. Chem., 2012, 19(16), 2534-2547.
[http://dx.doi.org/10.2174/092986712800492968] [PMID: 22489715]
[52]
Yancy, C.W.; Jessup, M.; Bozkurt, B.; Butler, J.; Casey, D.E., Jr; Drazner, M.H.; Fonarow, G.C.; Geraci, S.A.; Horwich, T.; Januzzi, J.L.; Johnson, M.R.; Kasper, E.K.; Levy, W.C.; Masoudi, F.A.; McBride, P.E.; McMurray, J.J.; Mitchell, J.E.; Peterson, P.N.; Riegel, B.; Sam, F.; Stevenson, L.W.; Tang, W.H.; Tsai, E.J.; Wilkoff, B.L. American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. J. Am. Coll. Cardiol., 2013, 62(16), e147-e239.
[http://dx.doi.org/10.1016/j.jacc.2013.05.019] [PMID: 23747642]
[53]
Mueller, T.; Dieplinger, B.; Gegenhuber, A.; Poelz, W.; Pacher, R.; Haltmayer, M. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin. Chem., 2008, 54(4), 752-756.
[http://dx.doi.org/10.1373/clinchem.2007.096560] [PMID: 18375488]
[54]
Dieplinger, B.; Gegenhuber, A.; Haltmayer, M.; Mueller, T. Evaluation of novel biomarkers for the diagnosis of acute destabilised heart failure in patients with shortness of breath. Heart, 2009, 95(18), 1508-1513.
[http://dx.doi.org/10.1136/hrt.2009.170696] [PMID: 19525245]
[55]
Bayes-Genis, A.; Pascual-Figal, D.; Januzzi, J.L.; Maisel, A.; Casas, T.; Valdes Chavarri, M.; Ordonez-Llanos, J. Soluble ST2 monitoring provides additional risk stratification for outpatients with decompensated heart failure. Rev. Esp. Cardiol., 2010, 63(10), 1171-1178.
[http://dx.doi.org/10.1016/S0300-8932(10)70249-9] [PMID: 20875357]
[56]
Breidthardt, T.; Balmelli, C.; Twerenbold, R.; Mosimann, T.; Espinola, J.; Haaf, P.; Thalmann, G.; Moehring, B.; Mueller, M.; Meller, B.; Reichlin, T.; Murray, K.; Ziller, R.; Benkert, P.; Osswald, S.; Mueller, C. Heart failure therapy induced early ST2 changes may offer long-term therapy guidance. J. Card. Fail., 2013, 19(12), 821-828.
[http://dx.doi.org/10.1016/j.cardfail.2013.11.003] [PMID: 24239955]
[57]
Lassus, J.; Gayat, E.; Mueller, C.; Peacock, W.F.; Spinar, J.; Harjola, V.P.; van Kimmenade, R.; Pathak, A.; Mueller, T.; Disomma, S.; Metra, M.; Pascual-Figal, D.; Laribi, S.; Logeart, D.; Nouira, S.; Sato, N.; Potocki, M.; Parenica, J.; Collet, C.; Cohen-Solal, A.; Januzzi, J.L., Jr; Mebazaa, A. GREAT-Network. Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the Multinational Observational Cohort on Acute Heart Failure (MOCA) study. Int. J. Cardiol., 2013, 168(3), 2186-2194.
[http://dx.doi.org/10.1016/j.ijcard.2013.01.228] [PMID: 23538053]
[58]
Januzzi, J.L., Jr; Peacock, W.F.; Maisel, A.S.; Chae, C.U.; Jesse, R.L.; Baggish, A.L.; O’Donoghue, M.; Sakhuja, R.; Chen, A.A.; van Kimmenade, R.R.; Lewandrowski, K.B.; Lloyd-Jones, D.M.; Wu, A.H. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J. Am. Coll. Cardiol., 2007, 50(7), 607-613.
[http://dx.doi.org/10.1016/j.jacc.2007.05.014] [PMID: 17692745]
[59]
Boisot, S.; Beede, J.; Isakson, S.; Chiu, A.; Clopton, P.; Januzzi, J.; Maisel, A.S.; Fitzgerald, R.L. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J. Card. Fail., 2008, 14(9), 732-738.
[http://dx.doi.org/10.1016/j.cardfail.2008.06.415] [PMID: 18995177]
[60]
Kim, M.S.; Jeong, T.D.; Han, S.B.; Min, W.K.; Kim, J.J. Role of Soluble ST2 as a prognostic marker in patients with acute heart failure and renal insufficiency. J. Korean Med. Sci., 2015, 30(5), 569-575.
[http://dx.doi.org/10.3346/jkms.2015.30.5.569] [PMID: 25931787]
[61]
Rehman, S.U.; Mueller, T.; Januzzi, J.L., Jr Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J. Am. Coll. Cardiol., 2008, 52(18), 1458-1465.
[http://dx.doi.org/10.1016/j.jacc.2008.07.042] [PMID: 19017513]
[62]
Jin, M.; Wei, S.; Gao, R.; Wang, K.; Xu, X.; Yao, W.; Zhang, H.; Zhou, Y.; Xu, D.; Zhou, F.; Li, X. Predictors of long-term mortality in patients with acute heart failure. Int. Heart J., 2017, 58(3), 409-415.
[http://dx.doi.org/10.1536/ihj.16-219] [PMID: 28496020]
[63]
Mueller, T.; Gegenhuber, A.; Leitner, I.; Poelz, W.; Haltmayer, M.; Dieplinger, B. Diagnostic and prognostic accuracy of galectin-3 and soluble ST2 for acute heart failure. Clin. Chim. Acta, 2016, 463, 158-164.
[http://dx.doi.org/10.1016/j.cca.2016.10.034] [PMID: 27983996]
[64]
Manzano-Fernández, S.; Mueller, T.; Pascual-Figal, D.; Truong, Q.A.; Januzzi, J.L. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am. J. Cardiol., 2011, 107(2), 259-267.
[http://dx.doi.org/10.1016/j.amjcard.2010.09.011] [PMID: 21211603]
[65]
FriAes,F.;LourenAo,P.;Laszczynska,O.;Almeida,P.B.;Guimaraes,J.T.;Januzzi,J.L.;Azevedo,A.;Bettencourt,P.;Prognostic value of sST2 added to BNP in acute heart failure with preserved or reduced ejection fraction. Clin. Res.Cardiol., 2015, 104(6), 491-499.s.
[http://dx.doi.org/10.1007/s00392-015-0811-x] [PMID: 25586507]
[66]
Socrates, T.; deFilippi, C.; Reichlin, T.; Twerenbold, R.; Breidhardt, T.; Noveanu, M.; Potocki, M.; Reiter, M.; Arenja, N.; Heinisch, C.; Meissner, J.; Jaeger, C.; Christenson, R.; Mueller, C. Interleukin family member ST2 and mortality in acute dyspnoea. J. Intern. Med., 2010, 268(5), 493-500.
[http://dx.doi.org/10.1111/j.1365-2796.2010.02263.x] [PMID: 20804518]
[67]
Tousoulis, D.; Andreou, I.; Tsiatas, M.; Miliou, A.; Tentolouris, C.; Siasos, G.; Papageorgiou, N.; Papadimitriou, C.A.; Dimopoulos, M.A.; Stefanadis, C. Effects of rosuvastatin and allopurinol on circulating endothelial progenitor cells in patients with congestive heart failure: the impact of inflammatory process and oxidative stress. Atherosclerosis, 2011, 214(1), 151-157.
[http://dx.doi.org/10.1016/j.atherosclerosis.2010.11.002] [PMID: 21122851]
[68]
Andreou, I.; Tousoulis, D.; Miliou, A.; Tentolouris, C.; Zisimos, K.; Gounari, P.; Siasos, G.; Papageorgiou, N.; Papadimitriou, C.A.; Dimopoulos, M.A.; Stefanadis, C. Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: a randomized placebo-controlled study. Atherosclerosis, 2010, 210(1), 194-198.
[http://dx.doi.org/10.1016/j.atherosclerosis.2009.10.046] [PMID: 19962701]
[69]
Tousoulis, D.; Kampoli, A.M.; Siasos, G.; Stefanadi, E.; Antoniades, C.; Papavassiliou, A.G.; Stefanadis, C. Circulating biomarkers for the diagnosis and prognosis of heart failure. Curr. Med. Chem., 2009, 16(29), 3828-3840.
[http://dx.doi.org/10.2174/092986709789178000] [PMID: 19747138]
[70]
Aimo, A.; Vergaro, G.; Passino, C.; Ripoli, A.; Ky, B.; Miller, W.L.; Bayes-Genis, A.; Anand, I.; Januzzi, J.L.; Emdin, M. Prognostic value of soluble suppression of tumorigenicity-2 in chronic heart failure: a meta-analysis. JACC Heart Fail., 2017, 5(4), 280-286.
[http://dx.doi.org/10.1016/j.jchf.2016.09.010] [PMID: 27816512]
[71]
Meijers, W.C.; van der Velde, A.R.; Muller Kobold, A.C.; Dijck-Brouwer, J.; Wu, A.H.; Jaffe, A.; de Boer, R.A. Variability of biomarkers in patients with chronic heart failure and healthy controls. Eur. J. Heart Fail., 2017, 19(3), 357-365.
[http://dx.doi.org/10.1002/ejhf.669] [PMID: 27766733]
[72]
Piper, S.; deCourcey, J.; Sherwood, R.; Amin-Youssef, G.; McDonagh, T. Biologic variability of soluble ST2 in patients with stable chronic heart failure and implications for monitoring. Am. J. Cardiol., 2016, 118(1), 95-98.
[http://dx.doi.org/10.1016/j.amjcard.2016.04.017] [PMID: 27189812]
[73]
Yancy, C.W.; Jessup, M.; Bozkurt, B.; Butler, J.; Casey, D.E., Jr; Colvin, M.M.; Drazner, M.H.; Filippatos, G.S.; Fonarow, G.C.; Givertz, M.M.; Hollenberg, S.M.; Lindenfeld, J.; Masoudi, F.A.; McBride, P.E.; Peterson, P.N.; Stevenson, L.W.; Westlake, C. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart failure society of America. Circulation, 2017, 136(6), e137-e161.
[http://dx.doi.org/10.1161/CIR.0000000000000509] [PMID: 28455343]
[74]
Weinberg, E.O.; Shimpo, M.; Hurwitz, S.; Tominaga, S.; Rouleau, J.L.; Lee, R.T. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation, 2003, 107(5), 721-726.
[http://dx.doi.org/10.1161/01.CIR.0000047274.66749.FE] [PMID: 12578875]
[75]
Lichtenauer, M.; Jirak, P.; Wernly, B.; Paar, V.; Rohm, I.; Jung, C.; Schernthaner, C.; Kraus, J.; Motloch, L.J.; Yilmaz, A.; Hoppe, U.C.; Christian Schulze, P.; Kretzschmar, D.; Pistulli, R. A comparative analysis of novel cardiovascular biomarkers in patients with chronic heart failure. Eur. J. Intern. Med., 2017, 44, 31-38.
[http://dx.doi.org/10.1016/j.ejim.2017.05.027] [PMID: 28579310]
[76]
Ahmad, T.; Fiuzat, M.; Neely, B.; Neely, M.L.; Pencina, M.J.; Kraus, W.E.; Zannad, F.; Whellan, D.J.; Donahue, M.P.; Pina, I.L.; Adams, K.F.; Kitzman, D.W.; O’Connor, C.M.; Felker, G.M. Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure. JACC Heart Fail., 2014, 2(3), 260-268.
[http://dx.doi.org/10.1016/j.jchf.2013.12.004] [PMID: 24952693]
[77]
Wojciechowska, C.; Romuk, E.; Nowalany-Kozielska, E.; Jachec, W. Serum Galectin-3 and ST2 as predictors of unfavorable outcome in stable dilated cardiomyopathy patients. Hellenic J. Cardiol., 2017, 58(5), 350-359.
[http://dx.doi.org/10.1016/j.hjc.2017.03.006] [PMID: 28363768]
[78]
Gaggin, H.K.; Szymonifka, J.; Bhardwaj, A.; Belcher, A.; De Berardinis, B.; Motiwala, S.; Wang, T.J.; Januzzi, J.L., Jr Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure. JACC Heart Fail., 2014, 2(1), 65-72.
[http://dx.doi.org/10.1016/j.jchf.2013.10.005] [PMID: 24622120]
[79]
Felker, G.M.; Fiuzat, M.; Thompson, V.; Shaw, L.K.; Neely, M.L.; Adams, K.F.; Whellan, D.J.; Donahue, M.P.; Ahmad, T.; Kitzman, D.W.; Pina, I.L.; Zannad, F.; Kraus, W.E.; O’Connor, C.M. Soluble ST2 in ambulatory patients with heart failure: Association with functional capacity and long-term outcomes. Circ Heart Fail, 2013, 6(6), 1172-1179.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.113.000207] [PMID: 24103327]
[80]
Seo, S.M.; Kim, S.H.; Kim, Y.; Yoon, H.E.; Shin, S.J. Prognostic utility of soluble suppression of tumorigenicity 2 level as a predictor of clinical outcomes in incident hemodialysis patients. Int. J. Med. Sci., 2018, 15(7), 730-737.
[http://dx.doi.org/10.7150/ijms.23638] [PMID: 29910678]
[81]
Grakova, E.V.; Kopeva, K.V.; Teplyakov, A.T.; Ogurkova, O.N.; Garganeeva, A.A.; Garmaeva, O.V. Prognostic role of ST2 in patients with chronic heart failure of ischemic etiology and carbohydrate metabolism disorders. Ter. Arkh., 2019, 91(1), 32-37.
[http://dx.doi.org/10.26442/00403660.2019.01.000025] [PMID: 31090368]
[82]
Skali, H.; Gerwien, R.; Meyer, T.E.; Snider, J.V.; Solomon, S.D.; Stolen, C.M. Soluble ST2 and risk of arrhythmias, heart failure, or death in patients with mildly symptomatic heart failure: results from MADIT-CRT. J. Cardiovasc. Transl. Res., 2016, 9(5-6), 421-428.
[http://dx.doi.org/10.1007/s12265-016-9713-1] [PMID: 27798759]
[83]
Gaggin, H.K.; Motiwala, S.; Bhardwaj, A.; Parks, K.A.; Januzzi, J.L., Jr Soluble concentrations of the interleukin receptor family member ST2 and β-blocker therapy in chronic heart failure. Circ Heart Fail, 2013, 6(6), 1206-1213.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.113.000457] [PMID: 24114865]
[84]
Anand, I.S.; Rector, T.S.; Kuskowski, M.; Snider, J.; Cohn, J.N. Prognostic value of soluble ST2 in the valsartan heart failure trial. Circ. Heart. Fail, 2014, 7(3), 418-426.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.113.001036] [PMID: 24622243]
[85]
O’Meara, E.; Prescott, M.F.; Claggett, B.; Rouleau, J.L.; Chiang, L.M.; Solomon, S.D.; Packer, M.; McMurray, J.J.V.; Zile, M.R. Independent prognostic value of serum soluble ST2 measurements in patients with heart failure and a reduced ejection fraction in the PARADIGM-HF trial (prospective comparison of ARNI With ACEI to determine impact on global mortality and morbidity in heart failure). Circ Heart Fail, 2018, 11(5) e004446
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.117.004446] [PMID: 29748349]
[86]
Tseng, C.C.S.; Huibers, M.M.H.; Gaykema, L.H.; Siera-de Koning, E.; Ramjankhan, F.Z.; Maisel, A.S.; de Jonge, N. Soluble ST2 in end-stage heart failure, before and after support with a left ventricular assist device. Eur. J. Clin. Invest., 2018, 48(3) e12886.s
[http://dx.doi.org/10.1111/eci.12886] [PMID: 29325227]
[87]
Yucel, O.; Gul, I.; Zararsiz, A.; Demirpence, O.; Yucel, H.; Cinar, Z.; Zorlu, A.; Yilmaz, M.B. Association of soluble ST2 with functional capacity in outpatients with heart failure. Herz, 2018, 43(5), 455-460.
[http://dx.doi.org/10.1007/s00059-017-4590-1] [PMID: 28653113]
[88]
Ventoulis, I.; Mantziari, L.; Mouratoglou, S.A.; Kamperidis, V.; Giannakoulas, G.; Ziakas, A.; Tsalikakis, D.; Giamouzis, G.; Hitoglou-Makedou, A.; Karvounis, H. NGAL and ST2 levels in ambulatory patients with chronic heart failure. Clinical and echocardiographic correlates. Scand. Cardiovasc. J., 2015, 49(4), 213-219.
[http://dx.doi.org/10.3109/14017431.2015.1043141] [PMID: 25919009]
[89]
Zile, M.R.; Jhund, P.S.; Baicu, C.F.; Claggett, B.L.; Pieske, B.; Voors, A.A.; Prescott, M.F.; Shi, V.; Lefkowitz, M.; McMurray, J.J.; Solomon, S.D. Prospective comparison of ARNI with ARB on Management of Heart Failure With Preserved Ejection Fraction (PARAMOUNT) Investigators. Plasma biomarkers reflecting profibrotic processes in heart failure with a preserved ejection fraction: data from the prospective comparison of ARNI with ARB on management of heart failure with preserved ejection fraction study. Circ. Heart Fail., 2016, 9(1) e002551
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.115.002551] [PMID: 26754625]
[90]
Pacho, C.; Domingo, M.; Nunez, R.; Lupon, J.; Nunez, J.; Barallat, J.; Moliner, P.; de Antonio, M.; Santesmases, J.; Cediel, G.; Roura, S.; Pastor, M.C.; Tor, J.; Bayes-Genis, A. Predictive biomarkers for death and rehospitalization in comorbid frail elderly heart failure patients. BMC Geriatr., 2018, 18(1), 109.
[http://dx.doi.org/10.1186/s12877-018-0807-2] [PMID: 29743019]
[91]
AbouEzzeddine, O.F.; McKie, P.M.; Dunlay, S.M.; Stevens, S.R.; Felker, G.M.; Borlaug, B.A.; Chen, H.H.; Tracy, R.P.; Braunwald, E.; Redfield, M.M. Suppression of tumorigenicity 2 in heart failure with preserved ejection fraction. J. Am. Heart Assoc., 2017, 6(2) e004382
[http://dx.doi.org/10.1161/JAHA.116.004382] [PMID: 28214792]
[92]
Ruocco, G.; Evangelista, I.; Franci, B.; Lucani, B.; Martini, S.; Nuti, R.; Palazzuoli, A. Combination of ST2 and B-type natriuretic peptide in diabetic patients with acute heart failure: relation with ventricular stiffness and outcome. J. Cardiovasc. Med. (Hagerstown), 2019, 20(2), 81-90.
[http://dx.doi.org/10.2459/JCM.0000000000000741] [PMID: 30540645]
[93]
Najjar, E.; FaxA(c)n, U.L.; Hage, C.; Donal, E.; Daubert, J.C.; Linde, C.; Lund, L.H. ST2 in heart failure with preserved and reduced ejection fraction. Scand. Cardiovasc. J., 2019, 53(1), 21-27.
[http://dx.doi.org/10.1080/14017431.2019.1583363] [PMID: 30776920]
[94]
Giannessi, D. Multimarker approach for heart failure management: perspectives and limitations. Pharmacol. Res., 2011, 64(1), 11-24.
[http://dx.doi.org/10.1016/j.phrs.2011.03.006] [PMID: 21440629]
[95]
Kakkar, R.; Lee, R.T. Directions from Hecate: towards a multi-marker approach for heart failure assessment. Eur. J. Heart Fail., 2011, 13(7), 691-693.
[http://dx.doi.org/10.1093/eurjhf/hfr059] [PMID: 21712290]
[96]
de Boer, R.A.; Daniels, L.B.; Maisel, A.S.; Januzzi, J.L., Jr State of the Art: Newer biomarkers in heart failure. Eur. J. Heart Fail., 2015, 17(6), 559-569.
[http://dx.doi.org/10.1002/ejhf.273] [PMID: 25880523]
[97]
Bayes-Genis, A.; Nunez, J.; Nunez, E.; Martínez, J.B.; Ferrer, M.P.; de Antonio, M.; Zamora, E.; Sanchis, J.; Roses, J.L. Multi-biomarker profiling and recurrent hospitalizations in heart failure. Front. Cardiovasc. Med., 2016, 3, 37.
[http://dx.doi.org/10.3389/fcvm.2016.00037] [PMID: 27777932]
[98]
Lupon, J.; de Antonio, M.; Galan, A.; Vila, J.; Zamora, E.; Urrutia, A.; Bayes-Genis, A. Combined use of the novel biomarkers high-sensitivity troponin T and ST2 for heart failure risk stratification vs conventional assessment. Mayo Clin. Proc., 2013, 88(3), 234-243.
[http://dx.doi.org/10.1016/j.mayocp.2012.09.016] [PMID: 23384388]
[99]
Dupuy, A.M.; Curinier, C.; Kuster, N.; Huet, F.; Leclercq, F.; Davy, J.M.; Cristol, J.P.; Roubille, F. Multi-marker strategy in heart failure: combination of ST2 and CRP predicts poor outcome. PLoS One, 2016, 11(6) e0157159
[http://dx.doi.org/10.1371/journal.pone.0157159] [PMID: 27311068]
[100]
Nymo, S.H.; Aukrust, P.; Kjekshus, J.; McMurray, J.J.; Cleland, J.G.; Wikstrand, J.; Muntendam, P.; Wienhues-Thelen, U.; Latini, R.; Askevold, E.T.; Gravning, J.; Dahl, C.P.; Broch, K.; Yndestad, A.; Gullestad, L.; Ueland, T. CORONA Study Group. Limited added value of circulating inflammatory biomarkers in chronic heart failure. JACC Heart Fail., 2017, 5(4), 256-264.
[http://dx.doi.org/10.1016/j.jchf.2017.01.008] [PMID: 28359413]

Rights & Permissions Print Cite
Article Metrics
47
1
© 2024 Bentham Science Publishers | Privacy Policy